Biotecnol acquires all intellectual property rights related to the Tribody multispecific antibody platform.
North Brunswick, NJ – November 1, 2011 – Biotecnol, Inc. previously a fully owned subsidiary of Biotecnol SA, Oeiras, Portugal has acquired all intellectual property rights, know-how and materials to the Tribody platform from its affiliate company.
Biotecnol, Inc. has secured important funding from private individuals and private institutions in order to set-up its own business around the development of multifunctional antibody products. Bispecific antibody formats have emerged as a promising new path towards more effective antibody therapeutics. The value of this innovative and highly promising approach is reflected in the recent deal activity in this field. The total volume of deals in this space surpassed US $ 3 billion between 2009 and 2011 with single licensing deals at potential values varying between US $ 200 and 500 million. In January 2012, Amgen announced the acquisition of Micromet for US $ 1.2 billion in cash, providing an important validation for the whole field.
The Tribody format is one of the most versatile platforms in this space. The feasibility and inherent therapeutic value of this platform is already sparking significant interest within pharmaceutical companies. Biotecnol has achieved key milestones on the manufacturability of such antibodies as well on the selection and engineering of its bispecific and trispecific formats to be used in the oncology setting, where its pipeline is focused.
About Biotecnol, Inc.
Biotecnol, Inc. is a biotechnology company located in Durham NC, USA developing the next generation of antibody-based therapeutics for the treatment of diseases in a vast number of therapeutic areas and indications based on its proprietary Tribody™ technology. Biotecnol has fully integrated capabilities that allow the company to run and effectively manage its own drug development programmes, right from the antibody selection process to clinic proof of concept.
Tribody™ Platform
Tribodies are multifunctional recombinant antibody products which utilize the natural in vivo heterodimerization of Fd fragments and light chains of the Fab fragment to form a scaffold upon which additional functions can be incorporated, such as, additional binders, cytokines, chemokines, growth factors, enzymes or protein toxins covered under the Tribody™ patents. Due to its versatility, the platform allows for the engineering of multi-specificity targeting, whereby an antibody can be engineered to target either two or three different epitopes on the same target or two or three different targets in the same disease setting. Furthermore effector functions such as T-Cell or NK-Cell recruiting can be incorporated.